CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling

被引:89
|
作者
Mueller, Jennifer [1 ]
Obermeier, Ingrid [1 ]
Woehner, Miriam [1 ]
Brandl, Carolin [1 ]
Mrotzek, Sarah [1 ]
Angermueller, Sieglinde [1 ]
Maity, Palash C. [2 ,3 ,4 ]
Reth, Michael [2 ,3 ,4 ]
Nitschke, Lars [1 ]
机构
[1] Univ Erlangen Nurnberg, Chair Genet, Dept Biol, D-91058 Erlangen, Germany
[2] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Fac Biol, D-79108 Freiburg, Germany
[3] Univ Freiburg, Dept Mol Immunol, Fac Biol, D-79108 Freiburg, Germany
[4] Max Planck Inst Immunobiol & Epigenet, D-79108 Freiburg, Germany
关键词
B-lymphocyte differentiation; B-lymphocyte signaling; Siglecs; CD22-DEFICIENT MICE; NEGATIVE REGULATOR; IN-VIVO; RECEPTOR; ANTIGEN; GRB2; TRANSDUCTION; RECOGNITION; ACTIVATION; RESPONSES;
D O I
10.1073/pnas.1304888110
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A high proportion of human B cells carry B-cell receptors (BCRs) that are autoreactive. Inhibitory receptors such as CD22 can down-modulate autoreactive BCR responses. With its extracellular domain, CD22 binds to sialic acids in alpha 2,6 linkages in cis, on the surface of the same B cell or in trans, on other cells. Sialic acids are self ligands, as they are abundant in vertebrates, but are usually not expressed by pathogens. We show that cis-ligand binding of CD22 is crucial for the regulation of B-cell Ca2+ signaling by controlling the CD22 association to the BCR. Mice with a mutated CD22 ligand-binding domain of CD22 showed strongly reduced Ca2+ signaling. In contrast, mice with mutated CD22 immunoreceptor tyrosine-based inhibition motifs have increased B-cell Ca2+ responses, increased B-cell turnover, and impaired survival of the B cells. Thus, the CD22 ligand-binding domain has a crucial function in regulating BCR signaling, which is relevant for controlling autoimmunity.
引用
收藏
页码:12402 / 12407
页数:6
相关论文
共 50 条
  • [21] CD22 adhesion molecule ligand-dependent and -independent functions in vivo revealed in mice expressing CD22 receptors lacking ligand-binding activity
    Poe, JC
    Fujimoto, Y
    Hasegawa, M
    Miller, AS
    Haas, KM
    Fujimoto, M
    Tedder, TF
    FASEB JOURNAL, 2003, 17 (07): : C204 - C204
  • [22] SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux
    Ostrakhovitch, Elena A.
    Wang, Yefu
    Li, Shawn S-C.
    CELLULAR SIGNALLING, 2009, 21 (04) : 540 - 550
  • [24] ANTI-IGM-MEDIATED B-CELL SIGNALING - MOLECULAR ANALYSIS OF LIGAND-BINDING REQUISITES FOR HUMAN B-CELL CLONAL EXPANSION AND TOLERANCE
    RUDICH, SM
    ROUX, KH
    WINCHESTER, RJ
    MONGINI, PKA
    JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (01): : 247 - 266
  • [25] Impact of Ca2+ signaling on B cell function
    Baba, Yoshihiro
    Kurosaki, Tomohiro
    TRENDS IN IMMUNOLOGY, 2011, 32 (12) : 589 - 594
  • [26] TYROSINE PHOSPHORYLATION OF CD22 DURING B-CELL ACTIVATION
    SCHULTE, RJ
    CAMPBELL, MA
    FISCHER, WH
    SEFTON, BM
    SCIENCE, 1992, 258 (5084) : 1001 - 1004
  • [27] Ca2+ signaling and intracellular Ca2+ binding proteins
    Niki, I
    Yokokura, H
    Sudo, T
    Kato, M
    Hidaka, H
    JOURNAL OF BIOCHEMISTRY, 1996, 120 (04): : 685 - 698
  • [28] Expression and function of CD22, a B-cell restricted molecule
    Moyron-Quiroz, JE
    Partida-Sánchez, S
    Donís-Hernández, R
    Sandoval-Montes, C
    Santos-Argumedo, L
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (04) : 343 - 351
  • [29] CD22 is a negative regulator of B-cell receptor signalling
    Nitschke, L
    Carsetti, R
    Ocker, B
    Kohler, G
    Lamers, MC
    CURRENT BIOLOGY, 1997, 7 (02) : 133 - 143
  • [30] Epratuzumab: Targeting B-cell malignancies through CD22
    Coleman, M
    Goldenberg, DM
    Siegel, AB
    Ketas, JC
    Ashe, M
    Fiore, JM
    Leonard, JP
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3991S - 3994S